Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q2 FY27 Earnings Presentation
22 slides from Strides Pharma Science's earnings presentation, Oct 29, 2026
Slide 1: Exchange filing cover letter for earnings presentation
October 29, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051, Maharashtra. Dalal Street, Mumbai – 400 001, Maharashtra. Symbol: STAR Scrip Code: 532531 Dear Madam/ Sir, Sub: Earnings Presentation f
Slide 2: Q2 & H1FY27 Earnings Presentation
Q2 & H1FY27 Earnings Presentation October 29, 2026 Strides Pharma Science Limited Health where it matters
Slide 3: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 4: Strong Performance with Revenue at ₹14,297m, Grew ~17% YoY
Strides Delivers a Strong Performance with Revenue at ₹14,297m, Grew ~17% YoY; Ex-US Markets Grew 31% YoY EBITDA Grew 8% YoY to ₹2,509m, Despite increase in input material and freight cost due to geopolitical disruptions. Operational PAT at ₹1,358m with Operational EPS at ₹14.7; Reported PAT at ₹1,3
Slide 5: H1FY27 Performance: Revenue at ₹26,951m, Grew 15% YoY
H1FY27 Performance: Revenue at ₹26,951m, Grew 15% YoY EBITDA Grew 7% YoY to ₹4,807m; Operational PAT at ₹2,589m with Operational EPS at ₹28.1; Reported PAT at ₹2,996m Performance Highlights H1FY27 H1FY26 YoY change H1FY27 Performance Revenue (₹m) 26,951 23,406 ▲ 15.1% Revenue grew 15% YoY to ₹26,951
Slide 6: Predictable Growth Across Key Metrics Over the Last 10 Quarters
Predictable Growth Across Key Metrics Over the Last 10 Quarters Steady Compounding in Last 10 Quarters Total Revenue (₹m) EBITDA (₹m) Operational PAT (₹m) 11,537 10,543 11,669 11,904 11,197 12,208 11,946 13,235 12,654 14,297 1,846 1,900 2,103 2,179 2,181 2,316 2,359 2,397 2,298 2,509 1,130 1,140 1,2
Slide 7: Ex-US Growth Accelerates Diversification: Surpasses US Revenue
Ex-US Growth Accelerates Diversification: Surpasses US Revenue for the First Time in Q2FY27 Revenue Mix – H1 (%) US (₹m) +7% YoY Ex-US (₹m) +24% YoY Access* (₹m) +30% YoY Access Market Ex-US US 53% 49% 48% 44% ₹ 12,325 ₹ 13,137 ₹ 10,327 ₹ 12,838 ₹ 754 ₹ 976 3% 3% H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H
Slide 8: FY28 - $375m US Revenue Aspiration Update
FY28 - $375m US Revenue Aspiration Update Health where it matters
Slide 9: Growth Ambition Intact: US Revenue Aspiration Shifts Beyond FY28
Growth Ambition Intact: US Revenue Aspiration of ~$375m shifts beyond FY28; Ex-US acceleration and disciplined US Investment underpin the next phase of profitable growth US Market | Timing changes Strategic Response Ex-US Markets | Accelerating 7% Profitability-led growth Protect established profita
Slide 10: US Market
US Market Health where it matters
Slide 11: US Q2FY27 Revenue at ₹6,855m, Grew 9% YoY
Q2FY27 Revenue at ₹6,855m ($73m), Grew 9% YoY, H2 Expected to be Stronger with New Launches H1FY27 Performance (₹/$m) Comments • Q2FY27 revenue at $73m, 9% YoY growth ▲ 7% YoY • Launched 3 products in Q2FY27 ₹ 13,137 ₹ 12,325 • Continue to rank amongst the top 3 in 38 products, enjoying a market-lea
Slide 12: Ex-US Markets
Ex-US Markets Health where it matters
Slide 13: Ex-US Markets Revenue at ₹6,963m, Grew 31% YoY
Ex-US Markets Revenue at ₹6,963m ($74m), Grew 31% YoY, Driven by Strong Performance Across Markets H1FY27 Performance (₹/$m) Comments • All markets except US and institutional business form part of the Ex-US Markets ▲ 24% YoY ₹ 12,838 • QoQ growth led by expansion in the UK, Nordics and South Africa
Slide 14: Financial Performance
Financial Performance Strong Financial Discipline Enabled Profitable Growth Health where it matters
Slide 15: Income Statement – Q2FY27 Operational PAT at ₹1,358m
Income Statement – Q2FY27 Operational PAT at ₹1,358m; EPS at ₹14.7 Particulars (₹m) Q2FY27 Q2FY26 YoY Q1FY27 QoQ H1FY27 H1FY26 YoY I. Revenue 14,297 12,208 17.1% 12,654 13.0% 26,951 23,406 15.1% II. Material Costs 6,294 5,153 4,952 11,246 9,595 III. Gross Margin (I- II) 8,003 7,056 13.4% 7,702 3.9%
Slide 16: Reported Net Debt at ₹16,479m, Net Debt/EBITDA 1.72x
Reported Net Debt at ₹16,479m with a Net Debt/EBITDA of 1.72x Net Debt Rose by ₹2,114m in H1 to Fund Growth and Higher Working Capital Amid Geopolitical Disruptions; Remains at Comfortable Levels and Expected to Moderate in Coming Quarters Particulars (₹m) Mar’26 Sept’26 Q2 & H1FY27 update Working c
Slide 17: Key Metrics Remain Resilient Despite External Headwinds
Key Metrics Remain Resilient Despite External Headwinds Net Debt to Equity (x) Net Debt to EBITDA (x) Cash to Cash Cycle (Days) 137 0.98 3.47 129 124 117 0.59 1.90 0.46 0.47 1.72 1.55 FY24 FY25 FY26 Q2FY27 FY24 FY25 FY26 Q2FY27 FY24 FY25 FY26 Q2FY27 Current Ratio (x) RoCE (%) Fixed Asset Turnover Ra
Slide 18: Balance Sheet
Balance Sheet Strong Corporate Governance and Corporate Actions Improved the Balance Sheet Position Particulars (₹m) 31-Mar-24 31-Mar-25 31-Mar-26 30-Sep-26 Assets Net Tangible Assets (including CWIP) 8,809 9,220 10,756 11,369 Right-of-use assets 895 695 782 479 Goodwill and Other Intangibles 10,565
Slide 19: Corporate Governance
Corporate Governance Health where it matters
Slide 20: Mr. Biren Gabhawala Joins the Board as Independent Director
Strengthening Board Governance: Mr. Biren Gabhawala Joins the Board as Independent Director With his appointment*, Independent Directors will make up 6 of the 10 Board members Mr. Biren Gabhawala, Chartered Accountant (FCA) Biren, aged 60 years, is a Chartered Accountant with more than three decades
Slide 21: Q2 & H1FY27 Earnings Call Details
Q2 & H1FY27 Earnings Call Details Join through an operator using dial-in numbers Strides invites you to interact with the senior management on Q2 & H1FY27 performance Location Dial-in number October 30, 2026 India primary USA +91 22 6280 1434 / +91 22 7115 8838 18667462133 10:00 am IST / 4:30 am GMT
Slide 22: Thank You
Health where it matters Thank You Youtube logo Images - Free Download on Freepik To know more: www.strides.com investor-relations@strides.com Stay Connected © 2026 Strides Pharma All Rights Reserved. This presentation is intended solely for the use of the individual or entity to whom it is addressed
Strides Pharma Science — Q2 FY27 Earnings Presentation on 6ix